Drug effects on the hypothalamic pituitary axis Flashcards

1
Q

Describe the pathway for GH release and its effects?

A

GH released in response to GHRH and ghrelin from brain

Release inhibited by somatostain

Gh released from pituitary and travels to liver

Liver is stimulated to produce IGF-1 > effects of GH

IGF-1 provides negative feedback to pituitary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which parts of the GH pathway can go wrong?

A

Hormone insensitivity: can make a hormone that doesn’t work
End up with high levels of GH

Secondary deficiency: pituitary doesn’t produce growth hormone

Tertiary deficiency: no release of GH, because brain isn’t telling it to be released

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How can GH be administered? Why?

How often must it be administered? Why?

A

Parenteral administration only, as it has zero bioavailability after oral administration

Administered daily or multi-daily, as it has a short half-life in the plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does of GH is administered to patients?

A

Titrate dose to effect

Varies across patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the effect of Gh on T4?

A

GH can cause reduced T4 levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is somatotropin?

A

GH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the effect of modifying ghrelin on GH?

A

Get more GH release for any given level of GHRH in the presence of more ghrelin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

In which cases is treatment with IGF-1 useful?

A

GH insensitivity

Patients with anti-GH Ab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the side effects of treatment with IGF-1?

A

Like insulin > acute hypoglycaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the effects of having too much growth hormone?

A

Depending on when you have too much, can become very large (gigantism) or parts of your body can become very large (acromegaly)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the approach to treatment of excess GH?

A

Remove tumour

Reduce GH release

Inhibit GH action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How can tumours that are causing excess GH release be localised?

A

Use receptor kinetics to localise

Somatostatin receptors internalise upon activation, taking peptide ligand with them

Tumours expressing somatostatin receptors can be imaged by in vivo receptor scintigraphy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the approaches to reducing GH release?

A

Somatostatin administration

Somatostatin reduces GH release from pituitary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the effect of somatostatin administration?

A

Reduced GH release from pituitary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How is somatostatin administered?

A

Parenteral administration only

Short-half life > regular injections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

In which form is somatostatin administered?

Why?

A

Octreotide and lanreotide

Somatostain analogues that have been modified to prevent enzymatic cleavage and extend half-life (somatostain has a very short half-life)

17
Q

How is resistance to enzymatic cleavage commonly achieved?

A

Insert ‘unnatural’ D amino acids

18
Q

How can the effectiveness of treatment with somatostatin analogues be increased?

A

In some patients, addition of dopamine agonists

19
Q

How can GH action be inhibited?

A

Administration of GH antagonists

20
Q

How can GH receptor binding be disrupted?

A

Alter glycine at position 120 (addition of side chain in receptor prevents site 2 binding)

21
Q

Describe the pharmacokinetic properties of G120K-GH?

A

High affinity antagonist

Short half-life

22
Q

How is the half-life of G120K-GH increased?

A

PEGylation

Addition of PEG:
increases size, which reduces renal filtration
improves solubility
decreases access for proteolytic enzymes

23
Q

What is the problem with PEGylated G120K-GH?

How was this overcome?

A

PEGylation occurs at lysines, but there are two lysines involved in site 1 binding

So, end up with completely inactive molecule

Further mutated molecule to produce pegmisovant

24
Q

Describe the pathway for thyroid hormone release?

A

TRH > pituitary > TSH > thyroid gland > thyroid hormone

Thyroid hormone provides negative feedback to both pituitary and brain

25
Q

How is the thyroid hormone pathway affected in Grave’s disease?

A

Stimulatory Ab against thyroid gland > excessive release of thyroid hormone

Increased negative feedback to pituitary (decreased TSH) and brain (decreased TRH)

26
Q

How is the thyroid hormone pathway affected in Hashimoto’s disease?

A

Destructive Ab > loss of thyroid tissue > decreased thyroid hormone production

Loss of negative feedback to pituitary (increased TSH) and brain (increased TRH)

27
Q

How can hyperthyroidism due to Grave’s disease be treated?

A

Iodide > transiently reduce hormone synthesis and release

Radioactive 131I- > ablate thyroid gland

Carbimazole > inhibits thyroid peroxidase

Propylthiouracil > inhibits thyroid peroxidase and conversion of T4 to T3

28
Q

What is carbimazole used to treat?

Describe its action.

A

Used to treat hyperthyroidism

Inhbits thyroid peroxidase

29
Q

What is propylthiouracil used to treat?

Describe its action.

A

Used to treat hyperthryroidism

Inhibits thyroid peroxidase and conversion of T4 to T3

30
Q

What are thioamines?

A

Carbimazole and propylthiouracil

31
Q

Describe the side effects of treatment with thioamines?

A

May lead to goitre

May cause agranulocytosis

Propylthiouracil more likely to cause hepatotoxicity

32
Q

How is hypothyroidism treated?

A

Thyroxine administration

33
Q

Which protein binds thyroxine in the bloodstream?

A

Thyroxine binding globulin (TBG)

34
Q

When does thyroxine become active?

A

Mostly after conversion to T3

35
Q

Describe the pharmacokinetics of thyroxine?

A

Low Vd (99.6% protein bound, mostly TBG)

Long half-life

36
Q

Why is thyroxine treatment sometimes associated with initial poor compliance?

A

Slow accumulation and onset of action due to low Vd and long half-life

37
Q

How does liothyronine (T3) differ to thyroxine (T4)?

A

More active

Less strongly protein-bound > shorter half-life

Levels are less stable

38
Q
A